Christian B. Dinneen-Long
General Counsel bei GLYCOMIMETICS, INC.
Aktive Positionen von Christian B. Dinneen-Long
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GLYCOMIMETICS, INC. | General Counsel | 29.04.2019 | - |
| Unternehmenssekretär | 29.04.2019 | - |
Karriereverlauf von Christian B. Dinneen-Long
Ehemalige bekannte Positionen von Christian B. Dinneen-Long
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | General Counsel | - | - |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | General Counsel | - | - |
| Medimmune, Inc. | General Counsel | - | - |
Ausbildung von Christian B. Dinneen-Long
| Chicago-Kent College of Law | Graduate Degree |
| University of Wisconsin | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| General Counsel | 4 |
| Corporate Secretary | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GLYCOMIMETICS, INC. | Health Technology |
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Medimmune, Inc. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
